{"pmid":32292628,"pmcid":"PMC7118608","title":"A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System.","text":["A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System.","Engineering (Beijing)","Zhang, Yimin","Yu, Liang","Tang, LingLing","Zhu, Mengfei","Jin, Yanqi","Wang, Zhouhan","Li, Lanjuan","32292628"],"journal":"Engineering (Beijing)","authors":["Zhang, Yimin","Yu, Liang","Tang, LingLing","Zhu, Mengfei","Jin, Yanqi","Wang, Zhouhan","Li, Lanjuan"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292628","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.eng.2020.03.006","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664266295814651904,"score":8.233237,"similar":[{"pmid":32247038,"pmcid":"PMC7118642","title":"Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19.","text":["Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19.","Clin Immunol","Ma, Jie","Xia, Peng","Zhou, Yangzhong","Liu, Zhengyin","Zhou, Xiang","Wang, Jinglan","Li, Taisheng","Yan, Xiaowei","Chen, Limeng","Zhang, Shuyang","Qin, Yan","Li, Xuemei","32247038"],"journal":"Clin Immunol","authors":["Ma, Jie","Xia, Peng","Zhou, Yangzhong","Liu, Zhengyin","Zhou, Xiang","Wang, Jinglan","Li, Taisheng","Yan, Xiaowei","Chen, Limeng","Zhang, Shuyang","Qin, Yan","Li, Xuemei"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32247038","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.clim.2020.108408","keywords":["Blood purification","Critically ill COVID-19","Cytokine storm","IL-6","Plasma exchange"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135871365120,"score":120.08532},{"pmid":32283152,"title":"Cytokine Storm in COVID-19 and Treatment.","text":["Cytokine Storm in COVID-19 and Treatment.","Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration of some patients has been closely related to the cytokine storm in their bodies. This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment.","J Infect","Ye, Qing","Wang, Bili","Mao, Jianhua","32283152"],"abstract":["Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration of some patients has been closely related to the cytokine storm in their bodies. This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment."],"journal":"J Infect","authors":["Ye, Qing","Wang, Bili","Mao, Jianhua"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283152","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.037","keywords":["2019-nCoV","Coronavirus","Cytokine storm","Immunomodulation","SARS-CoV-2"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Cytokine"],"_version_":1664182200737726464,"score":88.315765},{"pmid":32205092,"title":"TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.","text":["TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.","COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.","J Microbiol Immunol Infect","Wu, Dandan","Yang, Xuexian O","32205092"],"abstract":["COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles."],"journal":"J Microbiol Immunol Infect","authors":["Wu, Dandan","Yang, Xuexian O"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205092","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.jmii.2020.03.005","keywords":["COVID-19","Cytokine storm","JAK2 inhibitor","SARS-CoV-2","TH17"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Fedratinib"],"_version_":1663352133701861377,"score":79.73025},{"pmid":32198066,"pmcid":"PMC7102657","title":"Advance of promising targets and agents against 2019-nCoV in China.","text":["Advance of promising targets and agents against 2019-nCoV in China.","Drug Discov Today","Duan, Yongtao","Zhu, Hai-Liang","Zhou, Chongchen","32198066"],"journal":"Drug Discov Today","authors":["Duan, Yongtao","Zhu, Hai-Liang","Zhou, Chongchen"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198066","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.drudis.2020.02.011","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352133592809472,"score":72.76879},{"pmid":32192578,"title":"COVID-19: consider cytokine storm syndromes and immunosuppression.","text":["COVID-19: consider cytokine storm syndromes and immunosuppression.","Lancet","Mehta, Puja","McAuley, Daniel F","Brown, Michael","Sanchez, Emilie","Tattersall, Rachel S","Manson, Jessica J","32192578"],"journal":"Lancet","authors":["Mehta, Puja","McAuley, Daniel F","Brown, Michael","Sanchez, Emilie","Tattersall, Rachel S","Manson, Jessica J"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32192578","week":"202012|Mar 16 - Mar 22","doi":"10.1016/S0140-6736(20)30628-0","link_comment_in":"32238976","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352133527797762,"score":71.185875}]}